Abstract

PROMISING AND NOVEL PROCEDURES FOR GLAUCOMA THERAPY: DOES MEDICAL ADHERENCE SEEM TO BE DEVELOPING?

*Chetan D. Shende, Dr. Nitin B. Kohale, Gajanan M. Jawalkar, Dr. H. S. Sawarkar

ABSTRACT

Glaucoma is a degenerative eye illness that is the biggest cause of irreversible blindness in the world. It is defined primarily by optic nerve destruction, which is frequently associated with high intraocular pressure. This study looks at the current pharmacological treatments for glaucoma, which include first-line medicines including prostaglandin analogues, beta-blockers, and the new class of Rho-kinase inhibitors. Furthermore, it investigates combination medications to improve therapy efficacy and solve adherence issues. Recent advances in neuro-protective techniques, gene therapy, and sustained-release drug delivery methods present intriguing alternatives to traditional IOP-lowering therapies. This review highlights the need for continued innovation in glaucoma therapy and management to improve patient outcomes. Glaucoma is a group of eye conditions that damagethe optical nerve, frequently due to elevated intraocular pressure (IOP). It's the alternate leading cause of unrecoverable blindness broadly. Despite being treatable, patient non-compliance with specified curatives remains a significant challenge. This article delves into the pathophysiology of glaucoma, highlights arising remedial strategies, and examines how these inventions address issues of medical adherence.

Keywords: Glaucoma, intraocular pressure, neuroprotection, gene therapy, prostaglandin analogues, sustained-release.